1Wissler RW,Eilert ML,Schroeder MA,et al.Production of lipormatous and atheromatous arterial lesions in the albino rat.Arch Pathol,1954,57:333.
2Paigen B,Morrow A,Brandon C,et al.Variation in susceptibility to atherosclerosis among inbred strains of mice.Atherosclerosis,1985,57:65-73.
3Fleckenstein-Grun G,Frey M,Luley C,et al.Differentiation calcium and cholesterol-dominated types of atherosclerosis lesion:antiarteriosclerotic aspects of calcium antagonist.Cardiovas Phamacol,1991,18:s1-s9.
4Fleckenstein KN,Kehel L,Bouayadi EF,et al.New model of atherosclerosis in insulin resistant sand rats:hypercholesterolemia combined with D2 vitamin.Atherosclerosis,2000,150:55-61.
5Kramsch DM.Atherosclerosis progression/regression:lipoprotein and vessel wall.Atherosclerosis,1995,118:s29-36.
6Weinstein DB,Heider JG.Antiatherogenic properties of Calcium Antagonists determinants.Am J Cardiol,1987,59:163B-172B.
9Joen RS,Ching HW,Yi CC,et al.Mechanisms in the inhibition of neointimal hyperplasis with triflavin in a rat model of balloon angioplasty.Lab Clin Med,2001,13:270-277.
7Hertog MGL, Krombout D, Aravanis C, et al. Flavonoid intake and long-tern risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med, 1995, 155: 381-386.
8Hertog MGL, Feskens EJM, Krombout D. Antioxidant flavonols and corinary heart disease risk. Lancet , 1997, 349:699
9Tijburg LBM, Wiseman SA, Meijer GW, ET AL. Effects of green tea, black tea and dietary lionic antioxidants on LDL oxidizability and atherockerisusis in hypercholesterlsemic rabbits. Athermclerosis, 1997, 235:37-47.
10DzauVJ. Vascular rennin-engiotensin system and vascular protection. J Cardiol pharmac, 1993, 22 (Suppl 5): S1-S9.
